Skip to main content

Table 1 Baseline characteristics by treatment (%)

From: Safety and efficacy of lumefantrine-artemether (Coartem®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults

 

SP

N = 486

AL

N = 485

Mean weight (Kg) (SD)

56.4 (10.1)

56.3 (9.6)

Number of women (%)

245 (50.5)

230 (47.4)

Mean age (yr) (SD)

27.0 (8.9)

26.3 (8.3)

Mean body temperature (°C) (SD)

37.2 (1.2)

37.3 (1.3)

Mean white blood cell count (n*109/l) (SD)*

5.1 (1.8)

5.2 (1.8)

Mean Hb (g/l) (SD)

13.0 (2.2)

13.2 (2.3)

Mean (geometric) parasite density(/μl) (range)*

8787 (406 – 103680)

8405 (350–158894)

Gametocytes prevalence (n)(%)

16 (3.3)

18 (3.7)

 

N = 477

N = 481

Weakness (%)

344 (72.1)

365 (75.9)

Headache (%)

428 (89.7)

429 (89.2)

Muscle/joint pain (%)

316 (66.2)

318 (66.2)

Dizziness (%)

176 (36.9)

177 (36.7)

Nausea (%)

190 (39.9)

180 (37.5)

Vomiting (%)

104 (21.7)

113 (23.5)

Diarrhoea (%)

62 (13.1)

59 (12.2)

Abdominal pain (%)

172 (36.1)

163 (33.8)

Heart palpitations (%)

76 (16.0)

76 (15.7)

Backache (%)

105 (22.0)

119 (24.7)

Jaundice** (%)

51 (10.7)

104 (21.7)

Pallor** (%)

6 (1.3)

1 (0.3)

Dark urine (%)

51 (10.6)

48 (9.9)

  1. *Data on WBC were missing in 4 patients in the SP group and in 7 in the AL group. Parasite density was calculated based on the parasites/WBC ratio.
  2. ** Jaundice and pallor in 302 patients in the SP and and 301 in the AL group.